Lucie Low is the scientific program manager of the trans-NIH Tissue Chip for Drug Screening program. In this capacity, she serves as a liaison between funded investigators, NIH administrative and management staff, and external stakeholders, including the Food and Drug Administration, the Defense Advanced Research Projects Agency and representatives from the pharmaceutical industry. She manages more than 20 teams involved in the Tissue Chips for Disease Modeling, Tissue Chips in Space, and Tissue Chip Testing Centers initiatives, working with Danilo A. Tagle, Ph.D., M.S., to help translate NIH-funded basic research into the development of potentially transformational tools for drug development. Low also serves as the NIH-NASA liaison point of contact, working with the NCATS Director and NIH-NASA Liaison Christopher P. Austin, M.D., to consult on and facilitate collaborations between NIH and NASA on areas of overlapping agency interest. Additionally, she helps coordinate activities under the HHS-NASA Interagency Agreement(link is external) (PDF - 273KB), working with multiple HHS agencies on trans-agency partnerships.
Prior to joining NCATS in 2016, Low was an intramural research fellow at the National Center for Complementary and Integrative Health (NCCIH), working in the laboratory of Scientific Director M. Catherine Bushnell, Ph.D. Low’s research focused on non-pharmacological interventions for the prevention and reversal of chronic pain and on understanding the interactions between pain, emotion and cognition. As pain and nociception are broad fields, she performed research using a wide range of techniques, including molecular biology, animal behavior and cognition, and human brain imaging.
Low obtained her master’s degree and doctorate in neuroscience from University College London in 2010, and she received the John J. Bonica Trainee Fellowship to move to McGill University in Montreal, Canada, to begin her postdoctoral training. She joined NIH in 2012 as a visiting fellow at NCCIH.